Medically Integrated Dispensing Pharmacy: ASCO-Network for Collaborative Oncology Development & Advancement Standards Update Journal Article
| Authors: | Raez, L. E.; Gregg, X. T.; Doshi, G. K.; Freeswick, S.; Cox, A.; Dave, N.; Patel, K. B.; Dillmon, M. S.; Genschaw, S.; Bettencourt, E. V.; Peng, E.; Bell, E.; McCullough, S.; Wimbiscus, B.; Reff, M. |
| Article Title: | Medically Integrated Dispensing Pharmacy: ASCO-Network for Collaborative Oncology Development & Advancement Standards Update |
| Abstract: | ASCO Standards are evidence-based standards to provide frameworks for best practices in cancer care, following the standards development process as outlined in the ASCO Standards Policies and Procedures Manual. ASCO Standards follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines.Standards and other guidance ("Guidance") provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases, or stages of diseases. Guidance is based on review and analysis of relevant literature, and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 (online only) for more.PURPOSETo update standards for dispensing oral anticancer medications and supportive care medications using a medically integrated dispensing pharmacy (MIP).METHODSA multidisciplinary expert panel of oncology professionals integral to MIP and a patient representative participated in updating the guidelines. The revised standards address patient-centered and operational interventions of MIP that improve the access, quality, safety, and outcomes of prescribed oral anticancer medications or other supportive care medications. A systematic literature review was conducted to identify primary studies of interventions designed to improve MIP that were published between May 2019 and August 2024.RESULTSUsing studies that met the intervention criteria and studies that were useful in determining gaps that need to be addressed by MIP standards, the standards were revised, restructured, and expanded into two primary domains: patient-centered quality standards and operational quality standards. Domain 1 centers on health equity and social determinants of health, drug access, patient safety, education, and adherence to maximize treatment outcomes. Domain 2 focuses on logistics and care coordination and waste prevention.CONCLUSIONThese revised and expanded ASCO-Network for Collaborative Oncology Development & Advancement standards further enhance existing guidance to practices and outpatient clinics engaging in or planning to initiate MIP. The goal is to improve clinical outcomes and patient satisfaction through adherence to rigorous standards in oral anticancer medication management, patient safety, and care coordination.Additional information is available at www.asco.org/standards. © 2025 American Society of Clinical Oncology. |
| Journal Title: | JCO Oncology Practice |
| ISSN: | 2688-1527 |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2025-01-01 |
| Start Page: | OP |
| End Page: | 25 |
| Language: | English |
| DOI: | 10.1200/op-25-00279 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work